Innohaler, a DPI device that makes life easier for asthma and chronic obstructive pulmonary disease (COPD) has been developed.
The lungs are considered as one of the fragile organs, vulnerable to damage and susceptible to a wide range of diseases. Asthma and COPD are the major obstructive diseases, characterized by chronic obstruction of pulmonary airflow that interferes with normal breathing. Dry powder inhalers (DPIs) are considered the most preferred drug delivery platform for such patients.
‘Asthma and COPD contribute primarily to the burden of Obstructive Airway Disease (OAD). If we believe the statistics, the burden of OAD (Asthma & COPD) disease in India is already at an all-time high. Of the approximately nine patients with OAD in India, less than one patient has access to the right type of lung care. ‘
Asthma and COPD
Alkem is poised to fill a huge gap in accessibility for the treatment of respiratory diseases in India and has made a huge step forward in the pulse technology industry by introducing the Innohaler, a DPI device.
With the introduction of this device, Alkem is entering core inhalation therapy and it is expected that the drug will effectively reach the lungs in each inhalation with awareness and compliance programs. patient’s guard.
Speaking of this innovative leap, Sandeep Singh, CEO, Alkem Laboratories Ltd., stated, “This moment is like delivering on our promise to the millions of people who are not getting proper care. for obstructive airway diseases and a reminder that we must go further.
Entering core breathing therapy with the advent of drug delivery platform Innohaler a (DPI device), we are sure to play an important role in reducing India’s lung burden by propagating the right knowledge and awareness for all stakeholders, from the clinician to the patient. “
Source: IANS
